Aptar has announced its acquisition of Noble International, which specializes in training devices and patient onboarding for drug delivery devices, including inhalers. Noble makes respiratory trainers for both MDIs and DPIs with a variety of technologies including Bluetooth connectivity, actuation force simulation, and error detection/correction.
According to Aptar, “This acquisition furthers Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers through all stages of their drug development journey.” Earlier this year, Aptar acquired two other companies active in OINDP development and analysis: Nanopharm and Gateway Analytical.
Aptar President and CEO Stephan Tanda commented, “We are pleased to welcome the Noble team to the Aptar family. This strategic acquisition meets our disciplined approach of acquiring companies with strong positions in attractive markets, proprietary technologies and robust growth fundamentals. The combination of Noble and Aptar will bring additional value to our pharmaceutical customers as they seek to put more life-changing treatments into the hands of empowered patients. Together, we will work toward the ultimate goal of improving patient experiences and health outcomes.”
Aptar Pharma President Gael Touya added, “We look forward to working with Noble’s leadership and team of innovators as we continue to improve the patient onboarding process. This acquisition, which expands our services offerings in injectables and respiratory, continues our strategy of building services associated with our device portfolio and speaks to our unwavering commitment to helping patients improve adherence.”
Noble CEO Jeff Baker said, “Joining Aptar is an important step in our mission to support the healthcare community’s effort to improve patient outcomes through innovation, education and patient access. It is exciting to know that by leveraging the breadth of Aptar’s portfolio and global network, we will now reach more pharmaceutical partners, healthcare professionals, caregivers and ultimately, patients.”
Read the Aptar press release.
